Prozac Tapering Guide
fluoxetine
Boxed Warning
Suicidality risk in children, adolescents, and young adults under 25 during initial treatment.
Overview
Fluoxetine was the first SSRI approved in the US and remains one of the most widely prescribed antidepressants. It is approved for major depressive disorder, OCD, panic disorder, bulimia nervosa, and bipolar depression (in combination with olanzapine).
10mg, 20mg, 40mg, 60mg
Capsules: 10mg, 20mg, 40mg; Tablets: 10mg, 20mg, 60mg; Oral solution: 20mg/5mL; Delayed-release capsules (weekly): 90mg
Category C (risk cannot be ruled out)
Mechanism of Action
Selective serotonin reuptake inhibitor (SSRI) that blocks the serotonin transporter (SERT). Its active metabolite norfluoxetine is also a potent SSRI, contributing to an extremely long effective half-life.
Taper Notes
Very long half-life makes it one of the more forgiving SSRIs to taper. A gradual reduction is still recommended.
Hyperbolic Tapering Guidance
Long half-life provides built-in buffering. Still recommended to taper gradually rather than abrupt stop.
Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.
Tapering Protocol
Evidence-based phased reduction schedule. Always taper under medical supervision.
| Phase | Duration | Notes |
|---|---|---|
| Initial reductions | 4-6 weeks | Available capsule strengths allow straightforward reductions. The long half-life buffers each step. |
| Middle reductions | 4-6 weeks | Smaller capsule strengths or oral solution may be used. Most tolerate this phase well. |
| Final reductions | 4-8 weeks | The long half-life makes Prozac one of the more forgiving SSRIs to taper. Work with your prescriber on the final steps. |
Withdrawal Timeline
3-7 days after dose reduction (delayed by long half-life)
1-2 weeks
2-4 weeks
Uncommon due to long half-life. Some report emotional flatness for 4-6 weeks. Fluoxetine has the mildest withdrawal profile of all SSRIs.
Community Tips
Practical insights shared by members tapering Prozac. Not medical advice — always consult your prescriber.
- 1Prozac's long half-life means withdrawal symptoms may be delayed rather than absent. A gradual taper is still recommended — discuss a plan with your prescriber.
- 2Oral solution is available but many members taper successfully with capsule strengths alone due to the forgiving pharmacokinetics.
- 3A fluoxetine cross-taper is sometimes considered for difficult tapers, but this is a complex strategy that should be carefully evaluated with your prescriber.
- 4Track your symptoms in your taper journal — the long half-life means changes can take a week or more to feel.
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- MAOIs — contraindicated (allow 5 weeks washout due to long half-life)
- Thioridazine — contraindicated (QT prolongation)
- Pimozide — contraindicated
Food Interactions
- No significant food effect on absorption
- Grapefruit juice may modestly increase levels
- Avoid alcohol during treatment
Contraindications
- MAOIs within 14 days (5 weeks washout before starting MAOI)
- Thioridazine
- Pimozide
Toxicity
Serotonin syndrome at supratherapeutic doses. QT prolongation rarely reported. Lower toxicity in overdose compared to TCAs.
Pharmacokinetics
ADME Profile
Well absorbed after oral administration. Bioavailability ~72%. Tmax 6–8 hours. Food slightly delays absorption but does not affect overall extent.
~20–45 L/kg
Hepatic via CYP2D6 (primary) and CYP2C9 to the active metabolite norfluoxetine. Fluoxetine is a potent CYP2D6 inhibitor.
Renal (~80%, with ~2.5% as unchanged fluoxetine and ~10% as norfluoxetine). Fecal (~15%).
~94.5%
Apparent oral clearance ~600 mL/min; decreases with chronic dosing due to CYP2D6 inhibition.
Need a clinician who understands tapering?
Browse our map of deprescribing-informed providers worldwide.
Other Drug Profiles
Sources & References
Prozac (fluoxetine) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Encyclopedic & chemical databases
Neutral, high-authority entity references.
Regulatory sources
Official prescribing information and safety notices.
Peer-reviewed research
Primary literature cited in this taper guide.
- Horowitz MA, Taylor D 2019 — Tapering of SSRI treatment to mitigate withdrawal symptoms (hyperbolic taper) (The Lancet Psychiatry)
- Davies J, Read J 2019 — A systematic review into the incidence, severity and duration of antidepressant withdrawal effects (Addictive Behaviors)
- Framer A 2021 — The patient voice: an exploration of the experience of withdrawal from antidepressants (Therapeutic Advances in Psychopharmacology)
Clinical guidelines
Evidence-based deprescribing and prescribing standards.
Deprescribing-specific resources
Clinician-facing references on tapering protocols.
- Deprescribing.org — Evidence-based deprescribing algorithms from the Bruyère Research Institute
- Royal College of Psychiatrists — Stopping antidepressants — UK clinical guidance on safely discontinuing antidepressants
Patient-advocacy & lived-experience
Long-running communities documenting withdrawal experience.
- Surviving Antidepressants — tapering forum — Long-running community archive of antidepressant taper experiences
- Inner Compass Initiative — Withdrawal Project — Peer-led resources for psychiatric drug withdrawal
- Mad in America — antidepressant withdrawal archive — Journalism and personal narratives on SSRI/SNRI discontinuation
- RxISK — adverse drug reaction reporting — Independent database of patient-reported adverse effects
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.